PharmaResearch Co., Ltd. (KOSDAQ:A214450) agreed to Spin-Off Research, manufacturing and sales division of pharmaceuticals, medical devices, cosmetics on June 13, 2025. The Allocation ratio is of 0.2572056 to Amount ratio of 1 share. After the spin-off, the spin-off surviving company shall be a holding company in accordance with the Antitrust Regulation and Fair Trade Act i.e, PharmaResearch Holdings Co., Ltd. The plan of division may be partially modified or changed by the board of directors or the CEO before the general meeting of shareholders for approval of the plan of division, depending on changes in business, plans and circumstances of the spin-off company, consultation process with related organizations, or related laws and regulations, and may be changed during the approval process of the general meeting of shareholders. In addition, if the plan of division is approved by the extraordinary general meeting of shareholders scheduled to be held on October 17, 2025, it may be amended or changed by the resolution of the board of directors of the spin-off company or the decision of the CEO in the case of the resolution of the board of directors of the spin-off company in the case of amendments or changes to the extent that such modifications or changes are not disadvantageous to the shareholders of the surviving company or the new spin-off company unless the amendments or changes are reasonably necessary and (ii) the amendments or changes to the extent that they do not impair the homogeneity. Such modifications and changes shall be effective upon publication or publication in accordance with relevant laws and regulations. Listing plan of new shares of a spin-off company The spin-off company submits an application for preliminary examination for re-listing to the KOSDAQ market Base date for new stock allotment will be on October 31, 2025 and Scheduled listing date of new shares on December 10, 2025.
PharmaResearch Co., Ltd. (KOSDAQ:A214450) cancelled the Spin-Off Research, manufacturing and sales division of pharmaceuticals, medical devices, cosmetics on July 8, 2025.
PHARMA RESEARCH PRODUCTS Co., Ltd. is a Korea-based company principally engaged in the manufacture and distribution of pharmaceuticals, medical equipment and cosmetics. The Company mainly provides its products which can relieve wrinkles, repair skin wound, and relieve climacteric and others. The Company also provides health care products, which can improve body immune systems and liver functions, and relieve fatigue. I n addition, it offers vitamin products, medical equipment for beauty and others.The Company mainly provides its products in domestic market.
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
